Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Naphazoline
Drug ID BADD_D01531
Description Naphazoline is a rapid acting imidazoline sympathomimetic vasoconstrictor of ocular or nasal artierioles[L5804,L5807]. It acts to decrease congestion and is found in many over the counter (OTC) eye drops and nasal preparations[L5804,L5807]. Naphazoline was first developed in 1942 as a nasal formulation for congestion[A176609].
Indications and Usage Naphazoline is primarily indicated in conditions like Corneal vascularity, Hyperaemia, Itching, Nasal congestion, and can also be given in adjunctive therapy as an alternative drug of choice in Sinusitis
Marketing Status Prescription; Discontinued
ATC Code R01AA08; R01AB02; S01GA01
DrugBank ID DB06711
KEGG ID D08253
MeSH ID D009278
PubChem ID 4436
TTD Drug ID D0O6IZ
NDC Product Code Not Available
Synonyms Naphazoline | AK-Con | AK Con | Albalon | All Clear | Clear Eyes | Colirio Alfa | Idril | Miraclar | Nafazair | Naphazoline Hydrochloride | Hydrochloride, Naphazoline | Naphazoline Monohydrochloride | Monohydrochloride, Naphazoline | Naphazoline Nitrate | Nitrate, Naphazoline | Naphcon | Naphcon Forte | Optazine | Privine | Privin | Proculin | Siozwo | Tele-Stulln | Tele Stulln | Vasoclear | Vasocon | Vasocon Regular | Vasoconstrictor Pensa | Pensa, Vasoconstrictor | VasoNit | Afazol Grin
Chemical Information
Molecular Formula C14H14N2
CAS Registry Number 835-31-4
SMILES C1CN=C(N1)CC2=CC=CC3=CC=CC=C32
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Asthenia08.01.01.001--Not Available
Discomfort08.01.08.003--Not Available
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Endophthalmitis11.01.06.003; 06.04.05.009--
Erythema23.03.06.001--Not Available
Eye disorder06.08.03.001--Not Available
Eye pain06.08.03.002--
Headache17.14.01.001--
Hyperglycaemia14.06.02.002; 05.06.02.002--
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hypertension24.08.02.001--
Intraocular pressure increased13.07.04.002--Not Available
Keratitis06.04.02.002--
Lacrimation increased06.08.02.004--
Mydriasis17.02.11.003; 06.05.03.004--Not Available
Nausea07.01.07.001--
Nervousness19.06.02.003--Not Available
Ocular hyperaemia06.04.05.004--Not Available
Punctate keratitis06.04.02.003--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Tension19.06.02.005--Not Available
Vision blurred06.02.06.007; 17.17.01.010--
Xerosis08.01.03.016--Not Available
Eye oedema06.08.03.013--Not Available
Ocular discomfort06.08.03.008--Not Available
Accidental exposure to product12.06.02.002--Not Available
The 1th Page    1    Total 1 Pages